🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,136 results for “The First People's Hospital of Lianyungang” Clear

  1. Visilizumab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 3 small molecule active

    1 trial

  2. Ypeginterferon alfa-2b

    The First People's Hospital of Lianyungang

    Chronic Hepatitis B

    phase 3 small molecule completed

    3 trials

  3. decitabine

    The First People's Hospital of Lianyungang

    Acute Myelocytic Leukemia

    phase 3 small molecule active

    1 trial

  4. decitabine

    The First People's Hospital of Lianyungang

    Poor Graft Function

    phase 3 small molecule active

    1 trial

  5. didroxyprogesterone

    The First People's Hospital of Lianyungang

    Pregnancy Rate

    phase 3 small molecule active

    1 trial

  6. different degrees of adjustment of the injection interval

    The First People's Hospital of Lianyungang

    Exudative Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  7. donor lymphocyte infusion

    The First People's Hospital of Lianyungang

    Minimal Residual Disease

    phase 3 mab completed

    1 trial

  8. esophagectomy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 3 other active

    1 trial

  9. metformin

    The First People's Hospital of Lianyungang

    Polycystic Ovary Syndrome

    phase 3 small molecule completed

    1 trial

  10. mitoxantrone liposome, Ara-Cytarabine and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  11. mycophenolate mofetil 2 g per day

    The First People's Hospital of Lianyungang

    Lymphocytic Myocarditis (Disorder)

    phase 3 small molecule completed

    1 trial

  12. nab-paclitaxel combined with carboplatin

    The First People's Hospital of Lianyungang

    Epithelial Ovarian Carcinoma Stage III

    phase 3 small molecule active

    1 trial

  13. paclitaxel/anthracycline

    The First People's Hospital of Lianyungang

    Primary Breast Cancer

    phase 3 small molecule active

    1 trial

  14. patients undergo cVATS segmentectomy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer Stage I

    phase 3 other active

    1 trial

  15. probiotics, antibiotics or antidepressants

    The First People's Hospital of Lianyungang

    Irritable Bowel Syndrome

    phase 3 small molecule active

    1 trial

  16. recombinant human erythropoietin

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 3 small molecule active

    1 trial

  17. recombinant human thrombopoietin

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  18. rhTPO

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  19. the Shouhui Tongbian Capsule

    The First People's Hospital of Lianyungang

    OIC

    phase 3 small molecule active

    1 trial

  20. ticagrelor

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  21. venetoclax

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  22. "Endostar"

    The First People's Hospital of Lianyungang

    Esophageal

    phase 2 small molecule terminated

    1 trial

  23. 0.9% sodium chloride

    The First People's Hospital of Lianyungang

    Kidney Disease, Chronic

    phase 2 small molecule active

    1 trial

  24. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources